Literature DB >> 31583526

Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Tomoko Akahane1, Akira Hirasawa2,3, Issei Imoto4,5, Aki Okubo6, Manabu Itoh6, Yoshiko Nanki2, Tomoko Yoshihama2, Eichiro Tominaga2, Daisuke Aoki2.   

Abstract

Malignant peritoneal mesothelioma (MPeM) is a rare and aggressive form of malignant mesothelioma. Sufficient biological tools for studying the functional characteristics of this cancer have not been developed. Therefore, in this study, a novel human cancer cell line, KOG-1, was established from ascites fluids isolated from a 39-year-old Japanese woman with pemetrexed-resistant MPeM. Cells were dendritic or linear immediately after thawing, showed a jigsaw puzzle-like and spindle arrangement during growth, and formed monolayers without contact inhibition in two-dimensional (2D) culture. The population doubling time was 13.7 h. Karyotypic and molecular genetic analyses showed that chromosome numbers ranged from 62 to 142, with a peak of 73 with complicated copy number alterations. No germline BAP1 pathogenic variant was detected. Cells expressed various tumor markers of mesothelioma, such as calretinin, podoplanin, and Wilms tumor 1 (WT-1). Drug sensitivity and resistance testing with a set of 36 drugs using 2D and three-dimensional (3D) culture models demonstrated that KOG-1 cells showed high and low sensitivity to pemetrexed under 2D and 3D culture conditions, respectively, whereas control ovarian cancer cell lines showed low sensitivity to pemetrexed under both culture conditions. This newly established cell line will be a valuable biological resource to expand the feasibility of functional studies as well as drug testing for potential therapeutic purposes in MPeM.

Entities:  

Keywords:  Cell line; Drug sensitivity and resistance testing; Pemetrexed; Peritoneal mesothelioma; Two- and three-dimensional culture

Year:  2019        PMID: 31583526     DOI: 10.1007/s13577-019-00286-w

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  37 in total

Review 1.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 2.  Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.

Authors:  Dario Baratti; Shigeki Kusamura; Marcello Deraco
Journal:  J Surg Oncol       Date:  2011-01-31       Impact factor: 3.454

3.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

4.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.

Authors:  Tanya J Shaw; Mary K Senterman; Kerri Dawson; Colleen A Crane; Barbara C Vanderhyden
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

5.  High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment.

Authors:  Yukie Yoshii; Takako Furukawa; Atsuo Waki; Hiroaki Okuyama; Masahiro Inoue; Manabu Itoh; Ming-Rong Zhang; Hidekatsu Wakizaka; Chizuru Sogawa; Yasushi Kiyono; Hiroshi Yoshii; Yasuhisa Fujibayashi; Tsuneo Saga
Journal:  Biomaterials       Date:  2015-02-21       Impact factor: 12.479

6.  Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Raffit Hassan; Evan Alley; Hedy Kindler; Scott Antonia; Thierry Jahan; Somayeh Honarmand; Nitya Nair; Chan C Whiting; Amanda Enstrom; Ed Lemmens; Takahiro Tsujikawa; Sushil Kumar; Gina Choe; Anish Thomas; Katherine McDougall; Aimee L Murphy; Elizabeth Jaffee; Lisa M Coussens; Dirk G Brockstedt
Journal:  Clin Cancer Res       Date:  2019-07-01       Impact factor: 12.531

7.  The diploid genome sequence of an Asian individual.

Authors:  Jun Wang; Wei Wang; Ruiqiang Li; Yingrui Li; Geng Tian; Laurie Goodman; Wei Fan; Junqing Zhang; Jun Li; Juanbin Zhang; Yiran Guo; Binxiao Feng; Heng Li; Yao Lu; Xiaodong Fang; Huiqing Liang; Zhenglin Du; Dong Li; Yiqing Zhao; Yujie Hu; Zhenzhen Yang; Hancheng Zheng; Ines Hellmann; Michael Inouye; John Pool; Xin Yi; Jing Zhao; Jinjie Duan; Yan Zhou; Junjie Qin; Lijia Ma; Guoqing Li; Zhentao Yang; Guojie Zhang; Bin Yang; Chang Yu; Fang Liang; Wenjie Li; Shaochuan Li; Dawei Li; Peixiang Ni; Jue Ruan; Qibin Li; Hongmei Zhu; Dongyuan Liu; Zhike Lu; Ning Li; Guangwu Guo; Jianguo Zhang; Jia Ye; Lin Fang; Qin Hao; Quan Chen; Yu Liang; Yeyang Su; A San; Cuo Ping; Shuang Yang; Fang Chen; Li Li; Ke Zhou; Hongkun Zheng; Yuanyuan Ren; Ling Yang; Yang Gao; Guohua Yang; Zhuo Li; Xiaoli Feng; Karsten Kristiansen; Gane Ka-Shu Wong; Rasmus Nielsen; Richard Durbin; Lars Bolund; Xiuqing Zhang; Songgang Li; Huanming Yang; Jian Wang
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

Review 8.  Malignant Mesothelioma and Its Non-Asbestos Causes.

Authors:  Richard L Attanoos; Andrew Churg; Francoise Galateau-Salle; Allen R Gibbs; Victor L Roggli
Journal:  Arch Pathol Lab Med       Date:  2018-02-26       Impact factor: 5.534

9.  Differences between peritoneal and pleural mesothelioma in Lombardy, Italy.

Authors:  Carolina Mensi; Marco Mendola; Barbara Dallari; Maryam Sokooti; Ramin Tabibi; Luciano Riboldi; Dario Consonni
Journal:  Cancer Epidemiol       Date:  2017-10-23       Impact factor: 2.984

10.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors:  Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal:  Lancet Oncol       Date:  2019-01-16       Impact factor: 41.316

View more
  1 in total

Review 1.  Harnessing preclinical models for the interrogation of ovarian cancer.

Authors:  Tianyu Qin; Junpeng Fan; Funian Lu; Li Zhang; Chen Liu; Qiyue Xiong; Yang Zhao; Gang Chen; Chaoyang Sun
Journal:  J Exp Clin Cancer Res       Date:  2022-09-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.